The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021716 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Radwa A Eladwy und 5 weiteren Autor:innen. Beteiligte Einrichtung: NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Gastrointestinal Microbiome, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Western Sydney University.
Abstract (Originalsprache)
Despite recent advances in oncology, cancer has remained an enormous global health burden, accounting for about 10 million deaths in 2020. A third of the cancer cases in developing counties are caused by microbial infections such as human papillomavirus (HPV), Epstein-Barr Virus (EBV), and hepatitis B and C viruses. EBV, a member of the human gamma herpesvirus family, is a double-stranded DNA virus and the primary cause of infectious mononucleosis. Most EBV infections cause no long-term complications. However, it was reported that EBV infection is responsible for around 200,000 malignancies worldwide every year. Currently, there are no vaccines or antiviral drugs for the prophylaxis or treatment of EBV infection. Recently, the gut microbiota has been investigated for its pivotal roles in pathogen protection and regulating metabolic, endocrine, and immune functions. Several studies have investigated the efficacy of antiviral agents, gut microbial metabolites, and natural products against EBV infection. In this review, we aim to summarise and analyse the reported molecular mechanistic and clinical studies on the activities of gut microbial metabolites and natural medicines against carcinogenic viruses, with a particular emphasis on EBV. Gut microbial metabolites such as short-chain fatty acids were reported to activate the EBV lytic cycle, while bacteriocins, produced by Enterococcus durans strains, have shown antiviral properties. Furthermore, several natural products and dietary bioactive compounds, such as curcumin, epigallocatechin gallate, resveratrol, moronic acid, and andrographolide, have shown antiviral activity against EBV. In this review, we proposed several exciting future directions for research on carcinogenic viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.
- Faculty of Food Science and Technology, Vietnam National University of Agriculture, Trau Quy, Gia Lam, Hanoi 100000, Vietnam.
ORCID-Profile: Ravi Shah, Deep Jyoti Bhuyan
Förderung
- Western Sydney University
Zitieren
APA
Eladwy, R. A., Vu, H. T., Shah, R., Li, C. G., Chang, D., & Bhuyan, D. J. (2023). The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021716
Vancouver
Eladwy RA, Vu HT, Shah R, Li CG, Chang D, Bhuyan DJ. The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021716
BibTeX
@article{Eladwy2023,
author = {Eladwy, Radwa A and Vu, Hang Thi and Shah, Ravi and Li, Chun Guang and Chang, Dennis and Bhuyan, Deep Jyoti},
title = {The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021716}
}
EUVIMED